ASH

Researchers demonstrated that any reduction of dose intensity from 1.3 mg/m2 of bortezomib as a first-line treatment for untreated multiple myeloma patients is associated with inferior OS. Furthermore, it was suggested that the cumulative bortezomib dose be ≥20.75 mg for a better OS. Read More ›

Researchers examined subset of elderly newly diagnosed myeloma patients from the GEM2010 trial and split the patients into 2 arms determined by their cytogenetic abnormalities (high risk and standard risk). Patients with 1q gains were shown to have similar outcomes to those without q1 gains when treated with bortezomib plus melphalan and prednisone, followed by lenalidomide and dexamethasone. Read More ›

Modification of the current treatment regimen of RVD to “RVD-lite” provided better tolerability and enhanced clinical benefits in transplant-ineligible patients and proved to be particularly manageable in older populations, even with a wide variety of performance statuses at the beginning of the study. Read More ›

Investigators propose moving to a phase 2 evaluation after using a new treatment regimen that was well-tolerated in patients with progressive disease consisting of panobinostat at 20 mg 3 times a week every other week to ixazomib at target 4 mg weekly, 3 weeks on, 1 week off, with dexamethasone 20 mg on the day of and after ixazomib. Read More ›

A pharmacokinetic and safety study of ixazomib in patients with severe renal impairment or end-stage renal disease requiring hemodialysis demonstrated that this patient subgroup requires dose modification of ixazomib due to a 38% higher, unbound systemic exposure. Administration of ixazomib may be administered without regard to the timing of dialysis. Read More ›

This phase 3 study demonstrated that the all-oral therapy of ixazomib in combination with lenalidomide/dexamethasone significantly increased median PFS without a substantial increase in overall toxicity. A similar benefit was noted in patients with high-risk cytogenetics. Read More ›

Researchers present the final data for the secondary end point of overall survival across the entire study population of the phase 3 clinical trial PANORAMA 1, which evaluated panobinostat in combination with bortezomib and dexamethasone. Overall survival was not statistically significant. Read More ›

The VISTA study demonstrated good tolerability of VMP; however, in a subsequent phase 2 trial, there was a higher rate of treatment discontinuation than expected. In this study, investigators demonstrated lowering the intensity of VMP proved to be both safe and effective for newly diagnosed multiple myeloma (NDMM). Read More ›

A phase 1, multicenter study evaluated the use of PvD in patients with proteasome inhibitor–exposed and lenalidomide-refractory multiple myeloma to examine the maximum tolerated dose with secondary end points of safety, overall response rate, duration of response, and time to response. Read More ›

The phase 1/2 Alliance study sought to evaluate the safety and preliminary efficacy of the combination of ixazomib/pomalidomide/dexamethasone in patients with double-refractory multiple myeloma compared with the approved combination of pomalidomide/dexamethasone. Here, they report the phase 1 portion of the Alliance study. Read More ›